Healthcare: 17 A-Grades, Seven Insurance Disasters

The Bifurcation

Healthcare is two sectors pretending to be one. On one side: pharmaceutical companies, biotech, and medical devices generating FCF margins between 15% and 29%. On the other: health insurers grinding out 1-3% margins while moving billions through their systems.

Seventeen companies earned A-grades. Seven got F's. The median FCF margin sits at 16.1%, which sounds healthy until you realize it's being dragged down by an entire subsector that can't convert revenue to cash.

The Winners: Pharma and Devices

Gilead leads at 29.1% FCF margin with an A-grade and an improving trend. That's cash flow that keeps compounding without needing to reinvest everything back into the business. AbbVie sits right behind at 27.6%, though it picked up a B-grade and a declining trend. Bristol-Myers at 25.5% shows what happens when margin stays strong but trend direction becomes a problem: you get an A, but you're on watch.

Zoetis at 23.2% is the animal health play no one talks about enough. Stable trend, A-grade, and a business model that doesn't depend on blockbuster drug timelines. IDEXX at 22.9% tells a similar story in the veterinary diagnostics space. Both print cash, both stay consistent, both avoid the drama.

The device makers cluster in the mid-teens. Intuitive Surgical at 16.9%, Stryker at 16.1%, Boston Scientific at 15.5%. All A-grades. All generating enough cash to fund R&D without depending on capital markets. The improving trend on Intuitive and Stryker suggests the robotic surgery and orthopedic markets still have room to grow without margin compression.

The Problem Child: Eli Lilly

Lilly prints an 8.2% FCF margin and gets an F. That's not a typo. Revenue grew fast on the back of diabetes and weight loss drugs, but the cash flow didn't follow. When you're reinvesting heavily into manufacturing capacity and clinical trials, the cash conversion suffers. The market loves the story. The balance sheet says slow down.

Declining trend, debt sitting at multiple times FCF, and margins that would earn a C-grade in a normal sector. In healthcare, where the A-grade threshold starts at 15%, it's a failure. The revenue growth narrative is real. The cash flow story needs time to catch up.

The Insurers: Structural Problems

UnitedHealth at 3.4% FCF margin, Cigna at 3.1%, CVS at 1.8%, Elevance at 1.5%, Humana at 0.1%. All F-grades. All showing improving trends, which tells you where they've been more than where they're going.

Health insurance is a volume business with thin margins and regulatory constraints that make it hard to compound cash. You move billions in premiums, pay out billions in claims, and keep a sliver in the middle. The model works for shareholders through dividends and buybacks, but it doesn't generate the kind of FCF margins that earn respect in this sector.

The improving trends suggest operational improvements and cost discipline. The margins suggest this is still a low-return business from a cash flow perspective. When CVS tries to vertically integrate with pharmacy benefit management and retail clinics, it adds complexity without solving the fundamental margin problem.

The Outlier: Moderna

Moderna at -133.1% FCF margin is in a category by itself. The company burned through cash as COVID vaccine revenue collapsed and R&D spending stayed elevated. The improving trend means it's getting less bad, not good. F-grade, and it's not close.

The pipeline might justify the spending if something hits. Until then, this is a biotech bet wrapped in a cash burn rate that would make most sectors uncomfortable.

What the Trend Distribution Tells You

Twelve companies improving, five stable, twelve declining. That's a sector in flux. The improving names are either recovering from COVID disruptions (Moderna, insurers) or expanding margins through operational leverage (Biogen, IDEXX, Medtronic). The declining names are mostly facing patent cliffs or pricing pressure (AbbVie, Amgen, Pfizer, J&J).

Pfizer at 13.2% with a C-grade and declining trend is what happens when you ride a COVID windfall and then face the other side. Revenue contracts, costs stay elevated, and the margin compresses. Still investment-grade from a cash flow perspective, but momentum matters.

Debt Context: Manageable but Not Great

Average debt-to-FCF of 7.7x sits in the caution zone. Not crisis territory, but enough to knock some companies down a grade. In a sector where margins are strong at the top and weak at the bottom, debt becomes the differentiator.

Companies like Gilead and Vertex with strong margins and reasonable debt loads can weather downturns. Insurers with thin margins and higher debt multiples are one bad quarter away from problems. When we last looked at healthcare in April, the insurance subsector was already struggling. The trend improvements haven't fixed the structural margin issues.

Bottom Line

Healthcare earns its reputation as a defensive sector, but only if you stick to the names that print real cash. Seventeen A-grades concentrated in pharma, biotech, and devices. Seven F-grades clustered in insurance and speculative biotech.

The sector median of 16.1% looks solid until you realize it's being propped up by the top half while the bottom half struggles to stay positive. If you're buying healthcare for cash flow stability, stay in the top ten names. If you're buying for growth, understand that margin compression and R&D burn are part of the deal.

The trend split tells you this isn't a stable sector coasting on demographics. It's a sector being reshaped by drug pricing pressure, patent expirations, and changing reimbursement models. Seventeen A-grades give you plenty of options. Choose the ones with improving trends and margins above 15%.